Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 17, 2026

Eric Trump says family assets invested in 'broad market indexes' — Trump's own disclosure lists 3,642 individual trades

View original at finance.yahoo.com
Eric Trump says family assets invested in 'broad market indexes' — Trump's own disclosure lists 3,642 individual trades On May 14, the U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Congressional stock trading should be banned

    60% confidence

  • Trump is the first sitting president in modern history to disclose this volume of individual securities trading while in office

    60% confidence

  • Trump family assets are invested in broad market indexes

    60% confidence

  • Presidents are exempt from federal conflict-of-interest statutes that bar other executive-branch employees from acting on matters where they hold a financial stake; the STOCK Act requires disclosure but does not prohibit trading

    60% confidence

  • Trump's trading activity barely registered through 2025 before exploding in the first quarter of 2026

    60% confidence

Data points we hold from this source

Donald Trump · disclosure filing pages113 pages
Donald Trump · trading pace58 trades_per_market_day
Donald Trump · stock transactions total3642 individual_trades
Donald Trump · stock sales1296 individual_trades
Donald Trump · stock purchases2345 individual_trades
Donald Trump · bond purchases prior filings337 USD
Donald Trump · cumulative transaction value high750 USD
Donald Trump · cumulative transaction value low220 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com